Harrow Health logo

Wall Street analysts forecast that Harrow Health, Inc. (NASDAQ:HROW – Get Rating) will report $0.02 earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Harrow Health’s earnings. Harrow Health reported earnings per share of ($0.11) in the same quarter last year, which indicates a positive year over year growth rate of 118.2%. The business is scheduled to issue its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that Harrow Health will report full year earnings of ($0.05) per share for the current financial year, with EPS estimates ranging from ($0.08) to ($0.02). For the next fiscal year, analysts expect that the company will report earnings of $0.36 per share, with EPS estimates ranging from $0.31 to $0.41. Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that that provide coverage for Harrow Health.

Harrow Health (NASDAQ:HROW – Get Rating) last issued its earnings results on Thursday, March 10th. The company reported ($0.01) EPS for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.09). The firm had revenue of $20.19 million during the quarter, compared to the consensus estimate of $21.35 million. Harrow Health had a negative net margin of 26.10% and a negative return on equity of 5.29%. During the same period in the previous year, the firm earned $0.07 earnings per share.


Searching for the next Microcap stocks with disruptive potential? These companies will release their quarterly earnings very soon… And we have found 5 microcap stocks that could see a spike in share price.

Separately, Zacks Investment Research upgraded shares of Harrow Health from a “strong sell” rating to a “hold” rating in a report on Friday, May 6th.

In other news, major shareholder Opaleye Management Inc. bought 28,557 shares of Harrow Health stock in a transaction dated Tuesday, April 12th. The stock was purchased at an average price of $6.75 per share, for a total transaction of $192,759.75. Following the purchase, the insider now directly owns 3,165,000 shares in the company, valued at approximately $21,363,750. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 12.43% of the stock is currently owned by company insiders.

A number of large investors have recently made changes to their positions in HROW. Barclays PLC raised its stake in shares of Harrow Health by 119.8% during the 3rd quarter. Barclays PLC now owns 5,412 shares of the company’s stock worth $49,000 after purchasing an additional 2,950 shares during the period. Bank of America Corp DE grew its position in shares of Harrow Health by 466.4% during the 4th quarter. Bank of America Corp DE now owns 4,463 shares of the company’s stock valued at $39,000 after acquiring an additional 3,675 shares during the period. HighVista Strategies LLC increased its stake in shares of Harrow Health by 38.0% during the 3rd quarter. HighVista Strategies LLC now owns 14,211 shares of the company’s stock worth $129,000 after purchasing an additional 3,911 shares during the last quarter. First Trust Advisors LP raised its holdings in shares of Harrow Health by 14.1% in the 4th quarter. First Trust Advisors LP now owns 39,277 shares of the company’s stock worth $339,000 after purchasing an additional 4,865 shares during the period. Finally, BlackRock Inc. lifted its stake in Harrow Health by 1.2% in the first quarter. BlackRock Inc. now owns 436,528 shares of the company’s stock valued at $2,978,000 after purchasing an additional 5,261 shares during the last quarter. Hedge funds and other institutional investors own 44.50% of the company’s stock.

Shares of NASDAQ:HROW traded down $0.04 during trading on Friday, reaching $5.85. 207,150 shares of the stock were exchanged, compared to its average volume of 116,699. Harrow Health has a 1-year low of $5.40 and a 1-year high of $12.99. The stock has a fifty day moving average of $6.89 and a two-hundred day moving average of $8.27. The company has a debt-to-equity ratio of 6.56, a current ratio of 6.24 and a quick ratio of 5.81. The firm has a market cap of $158.13 million, a price-to-earnings ratio of -7.50 and a beta of 0.91.

About Harrow Health (Get Rating)

Harrow Health, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc, a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc, a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc, a commercial-stage pharmaceutical company that engages in developing and commercializing drug products.

See Also

Get a free copy of the Zacks research report on Harrow Health (HROW)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $1,000 in Harrow Health right now?

Before you consider Harrow Health, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Harrow Health wasn’t on the list.

While Harrow Health currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here


#Harrow #Health #NASDAQHROW #Expected #Post #Earnings #Share

Leave a Reply

Your email address will not be published.